Log In
Print
BCIQ
Print
Print this Print this
 

Heplisav (V270)

Also known as: HBV vaccine, Hepislav-B (HBV-ISS vaccine)

  Manage Alerts
Collapse Summary General Information
Company Dynavax Technologies Corp.
DescriptionHBV vaccine combining hepatitis B surface antigen (HBsAg) with a toll-like receptor 9 (TLR9) agonist
Molecular Target Hepatitis B surface antigen (HBsAg) ; Toll-like receptor 9 (TLR9)
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine
Latest Stage of DevelopmentPhase III
Standard IndicationHepatitis B virus (HBV)
Indication DetailsPrevent HBV infection; Prevent HBV infection caused by all known subtypes in adults ages 18-70 years and in patients with chronic kidney disease (CKD); Prevent HBV infection for patients with end-stage renal failure; Prevent HBV infection in chronic kidney disease (CKD) patients; Prevent HBV infection in patients on dialysis
Regulatory Designation U.S. - Undisclosed Review (Prevent HBV infection caused by all known subtypes in adults ages 18-70 years and in patients with chronic kidney disease (CKD))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today